Vestmark Advisory Solutions Inc. Has $595,000 Stock Position in Haleon plc (NYSE:HLN)

Vestmark Advisory Solutions Inc. boosted its stake in Haleon plc (NYSE:HLN) by 53.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 62,420 shares of the company’s stock after buying an additional 21,673 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Haleon were worth $595,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC grew its stake in Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after buying an additional 5,768,117 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Haleon by 49.9% during the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. Douglas Lane & Associates LLC grew its position in shares of Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after purchasing an additional 161,865 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Haleon during the 4th quarter worth approximately $42,193,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HLN shares. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Finally, HSBC restated a “hold” rating on shares of Haleon in a research report on Wednesday. Five research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Haleon currently has an average rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Stock Performance

NYSE HLN opened at $10.45 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $47.29 billion, a price-to-earnings ratio of 30.72, a P/E/G ratio of 2.82 and a beta of 0.25. The firm’s 50 day simple moving average is $9.68 and its 200 day simple moving average is $9.86. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, research analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. This is an increase from Haleon’s previous — dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. Haleon’s dividend payout ratio is presently 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.